Skip to main
SPRB

SPRB Stock Forecast & Price Target

SPRB Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 80%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Spruce Biosciences Inc is positioned favorably within the rare endocrine disorder market, particularly with its product candidate TA-ERT for Mucopolysaccharidosis Type IIIB (MPS IIIB), which has the potential for substantial market impact due to its differentiated mechanism of action and favorable dosing schedule. The company has secured up to $50 million in funding from Avenue Capital, contingent on achieving key regulatory milestones, which provides financial stability and the potential to support the development and launch of its therapies. Recent advancements in early diagnosis and increased awareness of MPS disorders, combined with the success of enzyme replacement therapies (ERTs) for similar conditions, further bolster the positive outlook for Spruce Biosciences's market positioning and revenue potential.

Bears say

Spruce Biosciences Inc is a late-stage biopharmaceutical company that has yet to commercialize any products, creating a significant financial risk as it continues to incur net losses, which are expected to persist at least until the potential commercialization of its product candidate, TA-ERT. Recent feedback from the FDA has raised questions regarding TA-ERT's approval path, while there are concerns related to slower-than-anticipated commercial uptake due to competition and market factors, alongside medium-term dilution risks. Moreover, the company must invest in building out the necessary infrastructure to effectively launch and market its therapeutic, further complicating its financial outlook amidst ongoing operational losses.

SPRB has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 80% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Spruce Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Spruce Biosciences Inc (SPRB) Forecast

Analysts have given SPRB a Buy based on their latest research and market trends.

According to 5 analysts, SPRB has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $213.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $213.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Spruce Biosciences Inc (SPRB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.